Fungal infections in patients after recovering from COVID-19: a systematic review.

IF 3.8 Q2 INFECTIOUS DISEASES

Therapeutic Advances in Infectious Disease Pub Date : 2024-05-04 eCollection Date: 2024-01-01 DOI:10.1177/20499361241242963

Juan R Ulloque-Badaracco, Cesar Copaja-Corzo, Enrique A Hernandez-Bustamante, Juan C Cabrera-Guzmán, Miguel A Huayta-Cortez, Ximena L Carballo-Tello, Rosa A Seminario-Amez, Miguel Hueda-Zavaleta, Vicente A Benites-Zapata

{"title":"Fungal infections in patients after recovering from COVID-19: a systematic review.","authors":"Juan R Ulloque-Badaracco, Cesar Copaja-Corzo, Enrique A Hernandez-Bustamante, Juan C Cabrera-Guzmán, Miguel A Huayta-Cortez, Ximena L Carballo-Tello, Rosa A Seminario-Amez, Miguel Hueda-Zavaleta, Vicente A Benites-Zapata","doi":"10.1177/20499361241242963","DOIUrl":null,"url":null,"abstract":"Background and aims: The presence of fungal infections has been described in patients after recovering from COVID-19. This study aims to conduct a systematic review of studies that reported fungal infections (Mucor spp., Pneumocystis jirovecii, or Aspergillus spp.) in adults after recovering from COVID-19.Methods: We performed a systematic review through PubMed, Web of Science, OVID-Medline, Embase, and Scopus. The study selection process was performed independently and by at least two authors. We performed a risk of bias assessment using the Newcastle-Ottawa Scale for cohort and case-control studies, and the Joanna Briggs Institute's Checklists for Case Series and Case Reports.Results: The systematic search found 33 studies meeting all inclusion criteria. There was a total population of 774 participants, ranging from 21 to 87 years. From them, 746 developed a fungal infection. In 19 studies, Mucor spp. was reported as the main mycosis. In 10 studies, P. jirovecii was reported as the main mycosis. In seven studies, Aspergillus spp. was reported as the main mycosis. Regarding the quality assessment, 12 studies were classified as low risk of bias and the remaining studies as high risk of bias.Conclusion: Patients' clinical presentation and prognosis after recovering from COVID-19 with fungal infection differ from those reported patients with acute COVID-19 infection and those without COVID-19 infection.","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"11 ","pages":"20499361241242963"},"PeriodicalIF":3.8000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070125/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361241242963","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: The presence of fungal infections has been described in patients after recovering from COVID-19. This study aims to conduct a systematic review of studies that reported fungal infections (Mucor spp., Pneumocystis jirovecii, or Aspergillus spp.) in adults after recovering from COVID-19.

Methods: We performed a systematic review through PubMed, Web of Science, OVID-Medline, Embase, and Scopus. The study selection process was performed independently and by at least two authors. We performed a risk of bias assessment using the Newcastle-Ottawa Scale for cohort and case-control studies, and the Joanna Briggs Institute's Checklists for Case Series and Case Reports.

Results: The systematic search found 33 studies meeting all inclusion criteria. There was a total population of 774 participants, ranging from 21 to 87 years. From them, 746 developed a fungal infection. In 19 studies, Mucor spp. was reported as the main mycosis. In 10 studies, P. jirovecii was reported as the main mycosis. In seven studies, Aspergillus spp. was reported as the main mycosis. Regarding the quality assessment, 12 studies were classified as low risk of bias and the remaining studies as high risk of bias.

Conclusion: Patients' clinical presentation and prognosis after recovering from COVID-19 with fungal infection differ from those reported patients with acute COVID-19 infection and those without COVID-19 infection.

查看原文本刊更多论文

COVID-19康复后患者的真菌感染：系统综述。

背景和目的：COVID-19康复后的患者中存在真菌感染的情况。本研究旨在对报道 COVID-19 后成人真菌感染（粘孢子菌属、肺孢子菌属或曲霉菌属）的研究进行系统回顾：我们通过 PubMed、Web of Science、OVID-Medline、Embase 和 Scopus 进行了系统性回顾。研究筛选过程由至少两名作者独立完成。我们使用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）对队列研究和病例对照研究进行了偏倚风险评估，并使用乔安娜-布里格斯研究所（Joanna Briggs Institute）的核对表对病例系列和病例报告进行了评估：系统检索发现 33 项研究符合所有纳入标准。共有 774 名参与者，年龄从 21 岁到 87 岁不等。其中 746 人感染了真菌。在 19 项研究中，报告的主要真菌病是粘孢子菌属。在 10 项研究中，报告的主要真菌病为 P. jirovecii。在 7 项研究中，曲霉菌属是主要的真菌病。在质量评估方面，12 项研究的偏倚风险较低，其余研究的偏倚风险较高：结论：感染真菌的 COVID-19 患者康复后的临床表现和预后与急性 COVID-19 感染和未感染 COVID-19 的患者不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Infectious Disease INFECTIOUS DISEASES-

CiteScore

5.30

自引率

8.80%

发文量

审稿时长

9 weeks